PERICLES VENTURES - Key Persons

Job Titles:

• Global Leader
• Transformative Leader Charting a Course of Success

Evan G. Greenberg is a global leader in insurance and beyond. He has a wealth of experience and expertise in the industry and a vision for the future. He is the Chairman and CEO of Chubb Group, a global insurance company, since 2004. He is a respected and influential figure in the business world and a champion of global cooperation and development. He is an example of how one can achieve success and make a positive impact on the world. Greenberg has almost five decades of experience in the insurance industry and previously worked at AIG for 25 years. He is also involved in international economic and foreign affairs, serving on the boards of several institutions.

Job Titles:

• President and Chief Executive Officer of Biotts

Jan Henk Hendriks is a seasoned professional with a 28-year career. He started by acquiring a solid scientific foundation before delving into business, adopting the traditional approach that he believes is optimal for science-driven enterprises. Jan's experience includes technical roles across various industries, with a pivotal entry into the pharmaceutical realm as an ingredients supplier. He evolved within the pharmaceutical landscape to become an API supplier and, now, a trailblazer in transdermal carrier technology. As he navigated different sectors, Jan's roles shifted from technical to commercial, accumulating responsibilities. Jan entered the chemical industry, catering to diverse markets with specialty ingredients and performance additives, shaping his path to the pharmaceutical sector. He values the stability of the pharmaceutical industry - with its emphasis on innovation, science, and technology - along with the satisfaction of contributing to patient well-being. He focuses on providing cutting-edge transdermal carrier technology, motivated by the opportunity to enhance therapeutics and facilitate patient-friendly delivery options. Jan's commitment to innovation aligns with the pharmaceutical industry's ethos, where research and development drive progress. His ultimate reward is the impact on patients - curing diseases, alleviating symptoms, or simplifying treatment processes. Jan Henk Hendriks is the President and Chief Executive Officer of Biotts, a clinical-stage start-up. He ensures the company's continuity, emphasizing fundraising initiatives to secure resources for ongoing operations. He recognizes the importance of human capital and nurtures and leads the talented individuals in Biotts who deliver scientific innovation for patients. Jan also takes a strategic stance on building and positioning the Biotts brand in the pharmaceutical industry. He tackles the challenges faced by innovators, such as convincing stakeholders that what was impossible is now possible. He navigates the conservative environment through strategic partnerships with industry leaders like Laboratoires Servier and Bioton. These collaborations demonstrate Biotts' technology applied to enhance medications for patients. His leadership showcases the impact of Biotts' technology, as shown by his collaboration with Bioton. The innovation provides a non-invasive alternative to injections, offering a patient-friendly experience and a single insulin patch instead of multiple injections. Jan believes these successes will convince and inspire the pharmaceutical industry. Additionally, Jan supported the team in steering Biotts through a milestone - the first clinical trial. This achievement affirms the efficacy and safety of Biotts' technology in humans and underscores the start-up's understanding of regulatory requirements and its ability to bring innovative solutions to market. Jan Henk Hendriks faced unique challenges as a leader because of his unconventional approach to seeking new opportunities and changing industries. Some might see his lack of industry-specific experience as a disadvantage, but Jan sees it as an advantage. He takes the road less traveled and brings a fresh perspective to each industry, approaching challenges holistically. One challenge Jan faced was the perception of industry-specific experience. He overcame the initial skepticism by using the advantages of a fresh viewpoint. He asked fundamental questions about the value created by the team: Is the innovation truly unique? Does it make a positive difference to customers or patients? What is the value, and does it resonate beyond the organization? Answering these questions from a new perspective helped Jan cut through complexities and clarify the value of the products or innovations. Another challenge in Jan's journey was adapting to change. Jan stayed nimble and open-minded in the face of changing landscapes and navigated uncertainties effectively. He changed industries frequently and was open to changes and shifts in the market. However, this flexibility required adapting to new environments, dynamics, and competitors.

Job Titles:

• Veteran Enhancing Sales in the Pharmaceutical Landscape

Recently, the COVID-19 pandemic has forced companies to work virtually and have their vendors serve them through virtual platforms. While some companies found the transition hard, Delta Point adapted nimbly to be able to teach and coach salespeople to effectively sell in a virtual, and at times, a hybrid market. Jerry Acuff (Founder and CEO of Delta Point) believes that this was as huge a shift for the company as it was for its customers. With a proven approach molded in his years of experience in the marketplace, Jerry partners with pharmaceutical organizations to help them launch their products in a highly competitive market where their product must stand out and execution of sales is required. He is well-versed in sales and sales leadership expertise, organizational change, and creating compelling sales verbiage. Jerry has been leading Delta Point for almost two decades and has been one of the mainstays of the company since its inception. In an intriguing conversation with Mirror Review, Jerry discussed his entrepreneurial journey, Delta Point's prowess as one of the leaders in the industry, and his future plans. Here are some of the snippets from the conversation.

Job Titles:

• CEO of Align Technology
• Visionary Leader
• Visionary Leader in Orthodontics

Joseph Hogan, the CEO of Align Technology, stands out as a prominent figure in the orthodontics industry. His career, which started from humble beginnings, has taken him to the helm of the company. This journey highlights the profound impact of visionary leadership and unwavering determination. Under his guidance, Align Technology has thrived, making significant advancements in orthodontic treatment and clear aligner technology. Joseph Hogan, a visionary leader, has transformed the orthodontics industry, instilling confidence through smiles. His career boasts induction into the Medical Device Hall of Fame, membership in the National Academy of Engineering, and honorary doctorates. Hogan's dedication to innovation and technology elevates global oral health standards. Under his guidance, Align Technology strives to make the world more beautiful through confident smiles. Hogan's journey from Pittsburgh to global acclaim exemplifies the profound impact of leadership and vision, inspiring all.

Job Titles:

• Access Insurance President and CEO
• Next Access Insurance President and CEO
• President and CEO of Access Insurance Underwriter, LLC

Phil and Lisa Wardell founded Access Insurance Underwriter, LLC, in January 2000, 24 years ago. Phil and Lisa wanted an agency that served the client's interests and genuinely shopped their policies at each and every renewal. Phil says that clients are tired of interacting with a chatbot or listening to a million prompts on a phone system. People want to speak with a live human being and solve their issues. Phil Wardell, President and CEO of Access Insurance Underwriter, LLC, recognized the need for a better approach after managing large agencies for about 15 years. He prioritized putting the client's interests first and ensuring that each year client policies were automatically and legitimately shopped with all available carriers guaranteeing the best rate and value to their clients.

Job Titles:

• Chief Executive Officer of EastGate Biotech Corp
• Prominent Leader in Innovative Drug Delivery Technologies

Rose C. Perri is the Chief Executive Officer of EastGate Biotech Corp, a pharmaceutical company focused on developing and commercializing innovative drug formulations and drug delivery technologies. With over 20 years of experience in managing and overseeing operations for both private and public companies, Rose has a proven track record of success in the biotech sector. She co-founded Biomin Therapeutics Corporation, a publicly-traded R&D biotech company, and served as a co-founder and executive at Generex Biotechnology Corporation for 16 years. Her extensive network within the pharmaceutical, biotechnology, regulatory, and financial industries makes her well-positioned to attract and manage potential partnerships and alliances for EastGate Biotech Corp. In addition to her involvement in the biotech sector, Rose has also managed a family-owned property investment and management company. As CEO of EastGate Biotech Corp, Rose is committed to leveraging her experience and expertise to drive the company's growth and deliver innovative solutions to patients in need. Rose believes that the role of a CEO has evolved over the years, especially with the impact of the COVID-19 pandemic. Work environments have shifted from traditional office settings to virtual and remote workspaces. Moreover, companies have increasingly outsourced some roles abroad, leading to more arms-length management. As a result, the CEO's focus has shifted to motivating employees, whether through their management teams or directly. Communication and engagement with employees are key to building enthusiasm and driving success. According to Rose, the CEO should make everyone feel that their role contributes to the success of the company as a whole and that they are part of something important.